JP7504409B2 - Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 - Google Patents
Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 Download PDFInfo
- Publication number
- JP7504409B2 JP7504409B2 JP2021500215A JP2021500215A JP7504409B2 JP 7504409 B2 JP7504409 B2 JP 7504409B2 JP 2021500215 A JP2021500215 A JP 2021500215A JP 2021500215 A JP2021500215 A JP 2021500215A JP 7504409 B2 JP7504409 B2 JP 7504409B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- virus infection
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179000A JP7673362B2 (ja) | 2018-07-09 | 2023-10-17 | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305910.4A EP3594206A1 (en) | 2018-07-09 | 2018-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP18305910.4 | 2018-07-09 | ||
| PCT/EP2019/068459 WO2020011810A1 (en) | 2018-07-09 | 2019-07-09 | Phenyl-n-quinoline derivatives for treating a rna virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179000A Division JP7673362B2 (ja) | 2018-07-09 | 2023-10-17 | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524481A JP2021524481A (ja) | 2021-09-13 |
| JP2021524481A5 JP2021524481A5 (https=) | 2022-06-23 |
| JPWO2020011810A5 JPWO2020011810A5 (https=) | 2022-06-23 |
| JP7504409B2 true JP7504409B2 (ja) | 2024-06-24 |
Family
ID=63035966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500215A Active JP7504409B2 (ja) | 2018-07-09 | 2019-07-09 | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 |
| JP2023179000A Active JP7673362B2 (ja) | 2018-07-09 | 2023-10-17 | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179000A Active JP7673362B2 (ja) | 2018-07-09 | 2023-10-17 | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12084422B2 (https=) |
| EP (2) | EP3594206A1 (https=) |
| JP (2) | JP7504409B2 (https=) |
| KR (1) | KR102758510B1 (https=) |
| CN (1) | CN112566899B (https=) |
| AU (1) | AU2019300100B2 (https=) |
| BR (1) | BR112021000331A2 (https=) |
| CU (1) | CU24674B1 (https=) |
| MX (1) | MX2021000089A (https=) |
| WO (1) | WO2020011810A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| US20230142547A1 (en) | 2020-03-20 | 2023-05-11 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating microRNA activity A-124 |
| WO2025149545A1 (en) * | 2024-01-11 | 2025-07-17 | F. Hoffmann-La Roche Ag | Heteroarylphenyl ether derivatives |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070197625A1 (en) | 2004-02-20 | 2007-08-23 | Les Laboratoraties Servier | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. |
| WO2012080953A1 (en) | 2010-12-15 | 2012-06-21 | Splicos | Compounds useful for treating aids |
| WO2015001518A1 (en) | 2013-07-05 | 2015-01-08 | Splicos | Bicyclic compounds useful for treating diseases caused by retroviruses |
| WO2016135053A1 (en) | 2015-02-23 | 2016-09-01 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| WO2016135055A1 (en) | 2015-02-23 | 2016-09-01 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| FR2830862A1 (fr) | 2001-10-16 | 2003-04-18 | Lipha | Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| DE602004020073D1 (de) | 2003-08-21 | 2009-04-30 | Osi Pharm Inc | 3-substituierte imidazopyridinderivate als c-kit-inhibitoren |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1697343B1 (en) | 2003-12-18 | 2009-07-01 | Tibotec Pharmaceuticals Ltd. | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| WO2006037117A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2574670T3 (es) | 2005-03-17 | 2016-06-21 | Janssen Sciences Ireland Uc | 1,3-Dihidro-bencimidazol-2-ilidenoaminas como inhibidores de replicación del virus sincicial respiratorio |
| US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
| US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
| FR2901273B1 (fr) | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| US20140187641A1 (en) | 2012-08-23 | 2014-07-03 | Gtx | Estrogen receptor ligands and methods of use thereof |
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| JP2011026251A (ja) * | 2009-07-27 | 2011-02-10 | Kowa Co | ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| US8846713B2 (en) | 2010-06-24 | 2014-09-30 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors |
| EP2505198A1 (en) | 2011-04-01 | 2012-10-03 | Société Splicos | Compounds for use as therapeutic agents affecting p53 expression and/or activity |
| WO2014164667A1 (en) | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| RU2628800C2 (ru) | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| US20160143884A1 (en) | 2014-11-26 | 2016-05-26 | Esanex, Inc. | Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) |
| PT3429998T (pt) | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
-
2018
- 2018-07-09 EP EP18305910.4A patent/EP3594206A1/en not_active Ceased
-
2019
- 2019-07-09 US US17/259,364 patent/US12084422B2/en active Active
- 2019-07-09 MX MX2021000089A patent/MX2021000089A/es unknown
- 2019-07-09 KR KR1020217001298A patent/KR102758510B1/ko active Active
- 2019-07-09 CU CU2021000006A patent/CU24674B1/es unknown
- 2019-07-09 BR BR112021000331-2A patent/BR112021000331A2/pt unknown
- 2019-07-09 JP JP2021500215A patent/JP7504409B2/ja active Active
- 2019-07-09 WO PCT/EP2019/068459 patent/WO2020011810A1/en not_active Ceased
- 2019-07-09 AU AU2019300100A patent/AU2019300100B2/en active Active
- 2019-07-09 CN CN201980045917.4A patent/CN112566899B/zh active Active
- 2019-07-09 EP EP19737536.3A patent/EP3820852A1/en active Pending
-
2023
- 2023-10-17 JP JP2023179000A patent/JP7673362B2/ja active Active
-
2024
- 2024-05-10 US US18/660,578 patent/US12479802B2/en active Active
-
2025
- 2025-10-15 US US19/359,300 patent/US20260035348A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070197625A1 (en) | 2004-02-20 | 2007-08-23 | Les Laboratoraties Servier | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. |
| WO2012080953A1 (en) | 2010-12-15 | 2012-06-21 | Splicos | Compounds useful for treating aids |
| WO2015001518A1 (en) | 2013-07-05 | 2015-01-08 | Splicos | Bicyclic compounds useful for treating diseases caused by retroviruses |
| WO2016135053A1 (en) | 2015-02-23 | 2016-09-01 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| WO2016135055A1 (en) | 2015-02-23 | 2016-09-01 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
Non-Patent Citations (1)
| Title |
|---|
| Bioorg Med Chem Lett，2011年，22(2)，1107-1110 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7673362B2 (ja) | 2025-05-09 |
| US20260035348A1 (en) | 2026-02-05 |
| US12084422B2 (en) | 2024-09-10 |
| KR20210052432A (ko) | 2021-05-10 |
| CA3103867A1 (en) | 2020-01-16 |
| US20240308964A1 (en) | 2024-09-19 |
| US20210309611A1 (en) | 2021-10-07 |
| MX2021000089A (es) | 2021-03-25 |
| US12479802B2 (en) | 2025-11-25 |
| EP3820852A1 (en) | 2021-05-19 |
| CU24674B1 (es) | 2023-08-08 |
| EP3594206A1 (en) | 2020-01-15 |
| WO2020011810A1 (en) | 2020-01-16 |
| AU2019300100A1 (en) | 2021-01-21 |
| AU2019300100B2 (en) | 2024-10-24 |
| CN112566899B (zh) | 2024-01-30 |
| BR112021000331A2 (pt) | 2021-04-06 |
| CU20210006A7 (es) | 2021-08-06 |
| JP2024053563A (ja) | 2024-04-15 |
| JP2021524481A (ja) | 2021-09-13 |
| KR102758510B1 (ko) | 2025-01-22 |
| CN112566899A (zh) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7673362B2 (ja) | Ｒｎａウィルス感染を処置する為のフェニル－ｎ－キノリン誘導体 | |
| JP7491513B2 (ja) | Ｒｎａウィルス感染を処置する為のアリール－ｎ－アリール誘導体 | |
| RU2805064C2 (ru) | Производные фенил-n-хинолина для лечения рнк-вирусной инфекции | |
| CA3103867C (en) | Phenyl-n-quinoline derivatives for treating an rna virus infection | |
| HK40040036B (zh) | 用於治疗rna病毒感染的苯基-n-喹啉衍生物 | |
| HK40040036A (en) | Phenyl-n-quinoline derivatives for treating a rna virus infection | |
| RU2815493C2 (ru) | Арил-n-арильные производные для лечения рнк-вирусной инфекции | |
| RU2803216C2 (ru) | Фенил/пиридил-n-фенил/пиридильные производные для лечения рнк-вирусной инфекции | |
| HK40039623B (zh) | 用於治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物 | |
| HK40039623A (en) | Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating rna virus infection | |
| HK40040882A (en) | Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating a rna virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231130 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20231130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240220 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240508 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240604 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7504409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |